1. Home
  2. PGEN vs RAPP Comparison

PGEN vs RAPP Comparison

Compare PGEN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGEN
  • RAPP
  • Stock Information
  • Founded
  • PGEN 1998
  • RAPP 2022
  • Country
  • PGEN United States
  • RAPP United States
  • Employees
  • PGEN N/A
  • RAPP N/A
  • Industry
  • PGEN Biotechnology: Pharmaceutical Preparations
  • RAPP
  • Sector
  • PGEN Health Care
  • RAPP
  • Exchange
  • PGEN Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • PGEN 493.0M
  • RAPP 439.4M
  • IPO Year
  • PGEN N/A
  • RAPP 2024
  • Fundamental
  • Price
  • PGEN $4.14
  • RAPP $23.20
  • Analyst Decision
  • PGEN Buy
  • RAPP Strong Buy
  • Analyst Count
  • PGEN 5
  • RAPP 3
  • Target Price
  • PGEN $7.50
  • RAPP $34.67
  • AVG Volume (30 Days)
  • PGEN 18.8M
  • RAPP 1.4M
  • Earning Date
  • PGEN 08-12-2025
  • RAPP 11-06-2025
  • Dividend Yield
  • PGEN N/A
  • RAPP N/A
  • EPS Growth
  • PGEN N/A
  • RAPP N/A
  • EPS
  • PGEN N/A
  • RAPP N/A
  • Revenue
  • PGEN $4,340,000.00
  • RAPP N/A
  • Revenue This Year
  • PGEN $253.63
  • RAPP N/A
  • Revenue Next Year
  • PGEN $699.64
  • RAPP N/A
  • P/E Ratio
  • PGEN N/A
  • RAPP N/A
  • Revenue Growth
  • PGEN N/A
  • RAPP N/A
  • 52 Week Low
  • PGEN $0.65
  • RAPP $6.43
  • 52 Week High
  • PGEN $5.23
  • RAPP $42.27
  • Technical
  • Relative Strength Index (RSI)
  • PGEN 64.19
  • RAPP 59.49
  • Support Level
  • PGEN $3.89
  • RAPP $14.11
  • Resistance Level
  • PGEN $5.23
  • RAPP $42.27
  • Average True Range (ATR)
  • PGEN 0.36
  • RAPP 2.98
  • MACD
  • PGEN -0.09
  • RAPP 0.96
  • Stochastic Oscillator
  • PGEN 32.30
  • RAPP 32.28

About PGEN Precigen Inc.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: